Minerva Neurosciences | NERV - Sales Revenues


Minerva Neurosciences reported $0 in Sales Revenues for its fiscal quarter ending in September of 2024.





Sales Change Date
Acadia Pharmaceuticals USD 307.96M 39.9M Jun/2026
Adma Biologics USD 114.5M 24.66M Mar/2026
ALKERMES USD 496.01M 103.1M Jun/2026
Alterity Therapeutics Limited AUD 596.04K 584.66K Dec/2025
AstraZeneca USD 15.38B 90M Jun/2026
BioCryst Pharmaceuticals USD 218.25M 188.3M Jun/2026
Bristol-Myers Squibb USD 12.97B 1.48B Jun/2026
Cipla INR 71.19B 5.78B Jun/2026
Clal Biotechnology ILS 3.41M 2M Dec/2022
Compugen USD 6.35M 60.98M Mar/2026
CSL USD 8.33B 4.79B Dec/2025
Eli Lilly USD 22.97B 3.17B Jun/2026
GlaxoSmithKline GBP 8.41B 781M Jun/2026
Grifols EUR 2B 306.7M Mar/2026
Halozyme Therapeutics USD 481M 104M Jun/2026
Ionis Pharmaceuticals USD 268M 22M Jun/2026
J&J USD 25.31B 1.21B Jun/2026
Merck USD 16.6B 310M Jun/2026
Minerva Neurosciences USD 0 0 Sep/2024
Neurocrine Biosciences USD 959M 148M Jun/2026
Novartis USD 14.41B 1.3B Jun/2026
Novavax USD 147.14M 76.69M Dec/2025
Pfizer USD 15.03B 530M Jun/2026
Roche Holding CHF 30.36B 14.71B Jun/2026
Sanofi EUR 11.95B 710M Jun/2026
Takeda JPY 1.22T 130B Jun/2026
Vanda Pharmaceuticals USD 198.77M 151.12M Dec/2024